What's Hot
View all perspectives
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of the annual #ACR2020 meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Robert B Chao, MD doctorRBC
4 years ago
SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA
1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks
2⃣Similar improvement in UPA 15mg vs. 30mg
3⃣Both doses similar or > Adalimumab
@RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0
Check on Pneumococcal Vaccination: Dr. Janet Pope
Dr. Janet Pope reviews abstracts #0456 and #0457 presented at the 2020 ACR annual meeting.
David Liew drdavidliew
4 years ago
The lung-joint axis in RA just keeps on getting stronger
Lung ACPA present in early untreated RA/CSA:
crossreact acetylated/carbamylated antigens
differ in effects on cell types (neut activation, fibroblasts, osteoclasts)
Isn't lung ACPA fascinating?
#ACR20 ABST1445 @RheumNow https://t.co/9VKSRYlndT
Dr. John Cush RheumNow
4 years ago
Dr. Jas Singh has shown theres been a decline In-Hospital Mortality in Vasculitis patients over 17 yrs (1998-2014) (using NIS data) #ACR20 Abst#1423 @jasvindermd https://t.co/rMJX5lRrLY https://t.co/aE2rJrMdDh
Pregnancy in Spondyloarthritis: Dr Richard Conway interviews Dr. Sinead Maguire
Dr. Conway interviews Dr. Maguire about abstract #1323 presented at the 2020 ACR annual meeting.
Dr. John Cush RheumNow
4 years ago
National Inpatient Sample claims: ANCA Assoc vasculitis pts hospitalized with acute MI (AMI) had a no increase in mortality rate (5.3% vs. 4.7%) during 2016-2017, suggesting potentially better control w/ new meds (RTX), less steroids #ACR20 Abstr#1424 https://t.co/TYELUAjm9d
Dr. John Cush RheumNow
4 years ago
Using National Inpatient Sample (NIS) claims, SSc pts hospitalized with acute MI (AMI) had a higher unadjusted inpatient mortality rate (9.17% vs. 4.68%; p=0.001)( (aOR=2.02) #ACR20 Abstr#1390 https://t.co/qWUMkJR40d
David Liew drdavidliew
4 years ago
Treat-to-target trials keep getting harder:
- rheum attitudes changed by prev trials so usual care is already v good
- ?less inflamm dx
- more ambitious goals
ASDAS LDA/40/20 and cost-effective not enough?
TICOSPA 'failed' a very high hurdle
@annamolto #ACR20 ABST1444 @RheumNow https://t.co/NWSUvAtouR
Adela Castro AdelaCastro222
4 years ago
Hispanic/Latino hospitalization rates are overwhelming but not surprising given the huge health care disparities our community faces. #ACR20 #DrFaucisaidso https://t.co/jEVx7cCh7a
Dr. John Cush RheumNow
4 years ago
Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option. #ACR20 Abstr#1357 #UTSW @AdelaCastro222 https://t.co/HnnPD6eXW5 https://t.co/Li30kkp3P1
Dr. John Cush RheumNow
4 years ago
1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap
Dr. Rachel Tate uptoTate
4 years ago
Dr. M. “Peggy” Crow’s #StateofArt lecture at #ACR20 reminds us that HCQ is the foundation of tx, to keep prednisone goal < 7.5mg/d, and that BEL works best in early dz (< 2 yrs) Summary slide provided. https://t.co/3LbWqwwOsr
David Liew drdavidliew
4 years ago
We were always taught that rheumatic disease ILD is v bad in pregnancy.
Fetal outcomes are def bad in severe ILD, but no maternal deaths/few Cx.
May not need to avoid pregnancy/electively terminate!
Largest-to-date cohort @dukemedicine n=94
@drbags71 #ACR20 ABST1446 @RheumNow https://t.co/E7BDHn8KJb
Dr. John Cush RheumNow
4 years ago
RheumNow’s expanded coverage of the annual #ACR2020 meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
Poster Hall